Merrimack Pharmaceuticals, Inc.

MACK · NASDAQ
Analyze with AI
3/31/2024
12/31/2023
9/30/2023
6/30/2023
Operating Activities
Net Income-$436-$240-$279-$391
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$48$48$48$47
Change in WC$226$30$167-$298
Other Non-Cash-$1,152-$133-$139-$26
Operating Cash Flow-$1,314-$295-$203-$668
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$225,000$0$0$0
Inv. Purchases$0-$5,932-$6,845-$8,811
Inv. Sales/Matur.$3,000$6,000$0$0
Other Inv. Act.$0$0$3,000-$9
Investing Cash Flow$228,000$68-$3,845-$8,811
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$1,485$133$0$209
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$1,485$133$0$209
Financing Cash Flow$1,485$133$0$209
Forex Effect$0$0$0$0
Net Chg. in Cash$228,171-$94-$4,048-$9,270
Supplemental Information
Beg. Cash$5,989$6,083$10,131$19,401
End Cash$234,160$5,989$6,083$10,131
Free Cash Flow-$1,314-$295-$203-$668